Becton, Dickinson and Company $BDX Shares Purchased by Capital Analysts LLC

Key Points

• Capital Analysts LLC increased its stake in Becton, Dickinson and Company by 8.6%, now holding 50,816 shares valued at approximately $11.64 million.
• Brokerages have recently adjusted ratings and price targets for BDX, with Citigroup downgrading it from a "strong-buy" to a "hold" and cutting the target price to $185.00.
• Becton, Dickinson and Company reported a quarterly earnings per share of $3.68, exceeding analysts' estimates, alongside a revenue of $5.51 billion.

Capital Analysts LLC increased its stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 8.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 50,816 shares of the medical instruments supplier's stock after acquiring an additional 4,035 shares during the period. Capital Analysts LLC's holdings in Becton, Dickinson and Company were worth $11,640,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Brighton Jones LLC grew its holdings in Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock valued at $401,000 after purchasing an additional 877 shares during the period. Hara Capital LLC grew its holdings in Becton, Dickinson and Company by 26.4% in the fourth quarter. Hara Capital LLC now owns 335 shares of the medical instruments supplier's stock valued at $76,000 after purchasing an additional 70 shares during the period. GeoWealth Management LLC grew its holdings in Becton, Dickinson and Company by 85.6% in the fourth quarter. GeoWealth Management LLC now owns 1,928 shares of the medical instruments supplier's stock valued at $437,000 after purchasing an additional 889 shares during the period. Freedom Investment Management Inc. grew its holdings in Becton, Dickinson and Company by 9.0% in the fourth quarter. Freedom Investment Management Inc. now owns 1,407 shares of the medical instruments supplier's stock valued at $319,000 after purchasing an additional 116 shares during the period. Finally, First Trust Advisors LP grew its holdings in Becton, Dickinson and Company by 5.2% in the fourth quarter. First Trust Advisors LP now owns 270,668 shares of the medical instruments supplier's stock valued at $61,406,000 after purchasing an additional 13,260 shares during the period. 86.97% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Becton, Dickinson and Company

In related news, Director Claire Fraser sold 863 shares of the business's stock in a transaction on Friday, August 8th. The stock was sold at an average price of $192.30, for a total value of $165,954.90. Following the sale, the director owned 23,143 shares in the company, valued at approximately $4,450,398.90. The trade was a 3.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael David Garrison sold 1,185 shares of the business's stock in a transaction on Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the sale, the executive vice president owned 4,887 shares in the company, valued at $881,077.23. This represents a 19.52% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 3,214 shares of company stock worth $579,206. 0.36% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several analysts have commented on the company. Barclays dropped their price objective on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a report on Tuesday, June 3rd. Raymond James Financial downgraded Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research report on Friday, May 2nd. Wall Street Zen upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Wells Fargo & Company raised their target price on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a research report on Friday, August 8th. Finally, Bank of America downgraded Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 target price on the stock. in a research report on Thursday, May 1st. Four analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $211.44.

Becton, Dickinson and Company Trading Up 1.5%

NYSE:BDX traded up $2.8730 on Friday, reaching $199.5030. The company's stock had a trading volume of 1,619,788 shares, compared to its average volume of 2,720,196. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. The firm has a market cap of $57.18 billion, a price-to-earnings ratio of 35.88, a price-to-earnings-growth ratio of 1.47 and a beta of 0.20. The stock has a 50 day moving average price of $180.65 and a 200 day moving average price of $195.60.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. The company had revenue of $5.51 billion for the quarter, compared to the consensus estimate of $5.50 billion. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The company's revenue for the quarter was up 10.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.50 earnings per share. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, equities analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be issued a $1.04 dividend. This represents a $4.16 annualized dividend and a dividend yield of 2.1%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company's payout ratio is currently 74.82%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.